BioLineRx (BLRX) Current Deferred Revenue (2023 - 2024)
BioLineRx's (BLRX) quarterly Current Deferred Revenue came in at $2.3 million in Q3 2024, down 58.83% quarter-over-quarter from $5.5 million in Q2 2024.
BioLineRx (BLRX) Current Deferred Revenue (2023 - 2024) Analysis & Trends
BioLineRx's Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $2.3 million for Q3 2024.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $2.3 million in Q3 2024; TTM through Sep 2024 was $2.3 million, a N/A change from a year earlier, with the FY2023 full-year figure at $13.0 million, changed N/A from the prior year.
- Current Deferred Revenue eased to $2.3 million in Q3 2024 per BLRX's latest filing, from $5.5 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $13.0 million in Q4 2023 and bottomed at $2.3 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | BioLineRx | 7.05 Bn | 7.06 Bn | 154,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.26 Mn |
| Jun 30, 2024 | 5.48 Mn |
| Mar 31, 2024 | 9.03 Mn |
| Dec 31, 2023 | 12.96 Mn |